
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Details : The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
